Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. is on track to file for early commercialization of its promising ALS treatment, PrimeC, in Canada by Q2 2025, potentially capturing a market valued at $100M to $150M annually. The company’s strategic move follows positive results from clinical trials and aims to address the unmet demand for effective ALS therapies. NeuroSense also plans to expand its reach, seeking regulatory approval in additional global markets.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
